Answers are grounded in this paper and cite their sources.
Randomised controlled trials on convalescent plasma in patients with COVID-19 have given conflicting results with regards to therapeutic benefit.1,2 Possible factors include previous seroconversion in recipients1 and late treatment when proinflammatory factors dominate tissue damage.2 Patients with impaired immune function due to B-cell depletion might develop chronic SARS-CoV-2 infections, which can be controlled by convalescent plasma transfusions.3
No takes yet. Share an insight, caveat, or question.
Rodionov et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: